A Four-Part Peptide Vehicle That Delivers Therapeutic Proteins Inside Cells — and Treats Liver Failure in Mice | Research

The takeaway

A modular chimeric peptide system solves the endosomal escape problem in protein delivery, successfully treating inflammation and acute liver failure when injected intravenously in mice.

4 modules
Cell-penetrating peptide + pH-sensitive peptide + protease sites + leucine zipper — each solving a different delivery barrier

What the researchers found

Researchers engineered a four-module chimeric peptide system that solves two major problems with cell-penetrating peptide drug delivery: poor endosomal escape (cargo gets trapped inside cellular compartments) and degradation in blood serum.

The system chains together: (1) a cell-penetrating peptide to enter cells, (2) a pH-sensitive membrane-active peptide that activates in acidic endosomes, (3) protease cleavage sites that release cargo when cut by endosome-specific enzymes, and (4) a leucine zipper that dimerizes the construct for enhanced function. When used to deliver the therapeutic protein phosphatase 1B (PTP1B) intravenously in mice, it successfully suppressed TNF-α-induced systemic inflammation and prevented acetaminophen-induced acute liver failure.

Why it matters

Many promising drug targets sit inside cells, but getting large protein drugs through cell membranes and out of endosomal traps has been a major barrier. This modular peptide system demonstrates that combining multiple functional peptide elements can overcome both challenges simultaneously, opening the door to a new class of protein-based drugs that work against intracellular targets.

The numbers in context

4-module chimeric peptide system · Enhanced endosomal escape via pH-triggered + protease-triggered dual mechanism · Suppressed TNF-α inflammation in mice · Prevented acetaminophen-induced liver failure in mice

How the study worked

The researchers designed and synthesized a four-module chimeric peptide, tested protein delivery efficiency in cell culture (in vitro), and validated therapeutic efficacy in two mouse models: TNF-α-induced systemic inflammatory response and acetaminophen-induced acute liver failure. The therapeutic protein PTP1B was fused to the chimeric peptide and delivered via intravenous injection.

Who was studied

BALB/c mice in two disease models (systemic inflammation and acute liver failure); cell lines for in vitro studies

What this study cannot tell us

This is a mouse study — efficacy and safety in humans are unknown. The specific therapeutic protein used (PTP1B) may behave differently than other cargo proteins. Manufacturing complexity of a four-module chimeric construct could pose challenges for clinical development. Long-term effects and immunogenicity were not assessed.

How to read the evidence

Preclinical study with in vitro and in vivo (mouse) data published in Nature Communications. Demonstrates therapeutic efficacy in animal disease models but has not been tested in humans.

When this study was published

Published in 2021. Intracellular protein delivery remains an active research frontier, and this modular approach continues to be relevant as the field explores alternatives to lipid nanoparticle delivery.

The bigger picture

Published in Nature Communications, this work addresses one of the fundamental bottlenecks in biologics development: intracellular delivery. Most antibody and protein drugs can only hit targets on cell surfaces or in the bloodstream. A reliable system for delivering proteins to intracellular targets could unlock therapies for diseases driven by signaling pathways inside cells — including many cancers, inflammatory conditions, and metabolic disorders.

Questions still open

Can this chimeric peptide system deliver other therapeutic proteins beyond PTP1B with similar efficiency?
What is the immunogenic profile of this four-module construct with repeated dosing?
How does the manufacturing cost and complexity of this system compare to other intracellular delivery approaches like lipid nanoparticles?

Common questions

What is the endosomal escape problem in drug delivery?

When cell-penetrating peptides carry drug cargo into cells, the cargo gets trapped in endosomes — small bubble-like compartments inside the cell. If the drug can't escape from the endosome, it gets degraded and never reaches its target. This chimeric peptide system solves this by using pH-sensitive peptides that activate in the acidic endosome environment plus enzyme-cleavable sites that release the cargo.

Could this technology be used for human treatments?

Not yet. This study proved the concept works in mice, successfully treating inflammation and liver failure. Before human use, the system would need extensive safety testing, manufacturing optimization, and clinical trials. But the modular design means it could potentially be adapted for many different therapeutic proteins.

Read the original research

Efficient intracellular delivery of proteins by a multifunctional chimaeric peptide in vitro and in vivo.

Nature communications, 12(1), 5131

View on PubMed ↗Publisher’s paper ↗

Citation

Yu, Siyuan; Yang, Han; Li, Tingdong; Pan, Haifeng; Ren, Shuling; Luo, Guoxing; Jiang, Jinlu; Yu, Linqi; Chen, Binbing; Zhang, Yali; Wang, Shaojuan; Tian, Rui; Zhang, Tianying; Zhang, Shiyin; Chen, Yixin; Yuan, Quan; Ge, Shengxiang; Zhang, Jun; Xia, Ningshao. (2021). Efficient intracellular delivery of proteins by a multifunctional chimaeric peptide in vitro and in vivo.. Nature communications, 12(1), 5131. https://doi.org/10.1038/s41467-021-25448-z